JP2025506206A5 - - Google Patents

Info

Publication number
JP2025506206A5
JP2025506206A5 JP2024547861A JP2024547861A JP2025506206A5 JP 2025506206 A5 JP2025506206 A5 JP 2025506206A5 JP 2024547861 A JP2024547861 A JP 2024547861A JP 2024547861 A JP2024547861 A JP 2024547861A JP 2025506206 A5 JP2025506206 A5 JP 2025506206A5
Authority
JP
Japan
Prior art keywords
ring
cancer
compound according
compound
cycloalkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/013118 external-priority patent/WO2023158679A2/en
Publication of JP2025506206A publication Critical patent/JP2025506206A/ja
Publication of JP2025506206A5 publication Critical patent/JP2025506206A5/ja
Pending legal-status Critical Current

Links

JP2024547861A 2022-02-15 2023-02-15 がん治療のためのチオストレプトンから着想された化合物及びその調製 Pending JP2025506206A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263310400P 2022-02-15 2022-02-15
US63/310,400 2022-02-15
US202263341238P 2022-05-12 2022-05-12
US63/341,238 2022-05-12
PCT/US2023/013118 WO2023158679A2 (en) 2022-02-15 2023-02-15 Thiostrepton-inspired compounds for treatment of cancer and preparation thereof

Publications (2)

Publication Number Publication Date
JP2025506206A JP2025506206A (ja) 2025-03-07
JP2025506206A5 true JP2025506206A5 (cg-RX-API-DMAC7.html) 2026-02-19

Family

ID=87579015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547861A Pending JP2025506206A (ja) 2022-02-15 2023-02-15 がん治療のためのチオストレプトンから着想された化合物及びその調製

Country Status (8)

Country Link
US (1) US20250144078A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479390A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506206A (cg-RX-API-DMAC7.html)
CN (1) CN119301105A (cg-RX-API-DMAC7.html)
AU (1) AU2023222756A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252219A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342492A (cg-RX-API-DMAC7.html)
WO (1) WO2023158679A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044744A2 (en) * 2022-08-26 2024-02-29 Wake Forest University Health Sciences Peroxiredoxin 3 inhibitors and methods of use for treating cancer
US20260069580A1 (en) * 2022-08-26 2026-03-12 Wake Forest University Health Sciences Peroxiredoxin 3 inhibitors and methods of use for treating cancer
WO2024044751A2 (en) * 2022-08-26 2024-02-29 Wake Forest University Health Sciences Peroxiredoxin 3 inhibitors and methods of use for treating cancer
WO2024173644A2 (en) * 2023-02-15 2024-08-22 Rs Oncology, Llc Select thiostrepton-inspired compounds for treatment of cancer and preparation thereof
TW202613105A (zh) * 2024-06-21 2026-04-01 美商Rs腫瘤學有限責任公司 用於治療癌症之經修飾之硫鏈絲菌肽啟發之化合物及其製備

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2576595B1 (en) 2010-05-30 2016-12-21 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
US9173952B2 (en) 2010-05-30 2015-11-03 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
WO2017095751A1 (en) * 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
EP3685846A1 (en) * 2019-01-24 2020-07-29 Genethon Use of thiostrepton or its derivatives for the treatment of genetic diseases linked to a protein conformational disorder

Similar Documents

Publication Publication Date Title
JP2007511504A5 (cg-RX-API-DMAC7.html)
JP2025160318A5 (cg-RX-API-DMAC7.html)
JP2024534840A5 (cg-RX-API-DMAC7.html)
JP2019516700A5 (cg-RX-API-DMAC7.html)
JP2006511534A5 (cg-RX-API-DMAC7.html)
JP2023126440A5 (cg-RX-API-DMAC7.html)
JP2005504039A5 (cg-RX-API-DMAC7.html)
JP2014513704A5 (cg-RX-API-DMAC7.html)
JP2011524422A5 (cg-RX-API-DMAC7.html)
JP2020517616A5 (cg-RX-API-DMAC7.html)
JP2010510215A5 (cg-RX-API-DMAC7.html)
RU2010154172A (ru) Соединения для лечения рака
JP2018516238A5 (cg-RX-API-DMAC7.html)
JP2020063289A5 (cg-RX-API-DMAC7.html)
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2022526220A5 (cg-RX-API-DMAC7.html)
FR2928151A1 (fr) Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique
JP2025118609A (ja) Nurr1受容体調節因子
JP2010518158A5 (cg-RX-API-DMAC7.html)
US20230348441A1 (en) Bicyclic compound that acts as crbn protein regulator
KR101129088B1 (ko) N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염
JP2023088996A5 (cg-RX-API-DMAC7.html)
JP2009529028A (ja) ルテニウム(ii)化合物
JP2019504833A5 (cg-RX-API-DMAC7.html)
JP2005511594A5 (cg-RX-API-DMAC7.html)